AVEUM FAMILY VAULT

1. WHAT IS BEING DISCLOSED

Aveum Systems is making available a limited, controlled demonstration of the AVEUM Family Vault, a genomic-gated digital asset vault workflow.

The evaluation is intended to allow an authorized institutional evaluator to understand how the Family Vault workflow operates before considering access to Aveum's production or Ethereum Mainnet protocol environment.

The evaluation environment allows the evaluator to:

• generate synthetic genomic test material;
• submit synthetic material through the GIS Tunnel;
• observe the derivation of test identity anchors;
• configure a Family Vault;
• configure subordinate Family Vault pods;
• provision testnet vault accounts;
• work with testnet source wallets through the designated MPC infrastructure; and
• observe the operational workflow associated with genomic-gated vault administration.

The evaluation is not a production deployment.

2. TESTNET DATA SCOPE

The evaluation environment uses synthetic genomic data only.

The test GIS is calibrated for synthetic Chr1 and Chr22 test data.

The production GIS is materially different. Production operation is designed around the applicable full genomic input and certified-laboratory workflow and is not limited to the synthetic Chr1/Chr22 evaluation configuration.

Accordingly:

The evaluation is intended to demonstrate the Family Vault operational workflow, not to reproduce the complete production genomic-processing environment.

The evaluator should therefore not infer production performance, production eligibility, production acceptance criteria, or production genomic coverage solely from the test environment.

3. SYNTHETIC DATA ONLY

The evaluation environment is designed exclusively for synthetic data.

For purposes of this disclosure:

"Synthetic Data" means artificially generated genomic sequences produced by Aveum's test-generation system that are not intended to correspond to a real individual.

"Real Data" means genomic information derived from an actual individual or biological sample, including, without limitation:

• WGS;
• VCF;
• FASTQ;
• BAM;
• CRAM;
• SNP arrays;
• mitochondrial DNA arrays;
• genomic sequencing data; or
• other genomic information associated with an actual individual.

Real Data must not be submitted to the evaluation environment.

The evaluator should assume that the test environment is not authorized, configured, or intended for processing real genomic information.

4. CONFIDENTIAL COMPUTING ENVIRONMENT

The evaluation operates through an Aveum-controlled confidential computing environment utilizing an AWS Nitro Enclave deployment.

The evaluation environment is designed so that the evaluator does not receive access to:

• enclave memory;
• enclave kernel internals;
• derivation salts;
• protected derivation parameters;
• protected identity tails;
• confidential panel composition;
• internal derivation logic; or
• other protected implementation details of the Aveum system.

The evaluator may observe the permitted outputs of the evaluation workflow but does not receive the underlying protected computation environment.

The enclave deployment may use measurement and attestation information, including PCR measurements, as part of Aveum's technical security architecture.

5. AVEUM FAMILY VAULT TEST CONFIGURATION

The AVEUM Family Vault evaluation is designed around the following test configuration:

Main Vault

One principal test vault may be configured for the evaluation.

Family Vault Sub-Vaults

Up to ten (10) Family Vault sub-vaults may be configured for the test.

Main-Vault Asset-Class Vaults

Up to ten (10) additional Main-Vault asset-class vaults may be configured in the applicable test configuration.

Source Wallets

The evaluation may provision or connect an AVEUM Source Wallet through the designated MPC infrastructure.

The exact number and configuration of test wallets may be controlled by the applicable evaluation environment and technical provisioning system.

6. TEST OPERATIONS

During the evaluation, the evaluator may be provided access to selected test operations, including:

1. assignment of a test Vault Allocation Number (VAN);
2. selection of the applicable Family Vault configuration;
3. provisioning of a test Source Wallet through the designated MPC infrastructure;
4. generation of synthetic genome pairs;
5. submission of synthetic genome material through the GIS Tunnel;
6. derivation of test genomic identity anchors within the confidential computing environment;
7. display of permitted identity outputs through the designated test interface;
8. configuration of Family Vault sub-vaults;
9. configuration of applicable folder or genomic-drop workflows;
10. disposal of test input material according to the evaluation environment's technical workflow; and
11. provisioning of testnet vault accounts on Sepolia or a successor Ethereum test network designated by Aveum.

The precise functions made available may vary according to the test configuration and technical environment.

7. TESTNET DIGITAL ASSETS

The evaluation is a testnet demonstration.

NO REAL DIGITAL ASSETS SHOULD BE PLACED INTO THE EVALUATION ENVIRONMENT.

Any testnet balances, testnet tokens, or testnet vault positions displayed during the evaluation are for demonstration and technical testing purposes only and should not be regarded as having monetary value.

Where Aveum makes utility tokens available for testing, those tokens are provided solely for evaluation of the applicable test workflow.

The evaluation does not itself confer:

• equity;
• ownership;
• dividends;
• profit participation;
• investment rights;
• securities;
• beneficial ownership of Aveum;
• rights to production tokens; or
• rights to production digital assets.

8. SOURCE WALLET AND MPC PROVIDER

The AVEUM Source Wallet may operate through an external or designated MPC infrastructure provider.

Where an external MPC provider is used, that provider may apply its own terms, KYC procedures, custody arrangements, authentication procedures, and compliance requirements.

Aveum operates at the applicable protocol or substrate layer and does not represent that it performs KYC or provides custody of assets held by an external MPC provider.

The evaluator should review the applicable MPC provider's terms before using any wallet or custody functionality.

9. EVALUATION WINDOW

The standard Family Vault evaluation window is twenty-four (24) consecutive hours beginning when the test environment is activated.

At the end of the evaluation window:

• test access may expire automatically;
• test credentials or evaluation keys may become inactive;
• testnet vault access may cease;
• test data and test-environment backups may be deleted in accordance with Aveum's technical procedures; and
• the evaluator should not assume that any test environment, test vault, test wallet, or test configuration will remain recoverable.

The evaluation does not automatically convert into production access.

10. MACHINE AND TEST ENVIRONMENT IDENTIFICATION

For technical security, fraud prevention, abuse prevention, and test-environment administration, Aveum may associate a test environment with technical identifiers such as:

• a Machine ID;
• machine fingerprint;
• IP address;
• device identifier;
• test Vault Allocation Number; and
• evaluation activation information.

These identifiers may be used to prevent repeated or unauthorized creation of evaluation environments and to maintain the integrity of the test infrastructure.

The technical identification of a device does not constitute a requirement that the evaluator disclose its personal identity to Aveum.

11. PROHIBITED TEST ACTIVITY

The following activities are outside the intended scope of the evaluation:

• submission of real genomic data;
• submission of personal genomic information;
• attempting to access enclave memory;
• attempting to extract protected derivation information;
• attempting to circumvent the evaluation timer or access controls;
• attempting to reverse engineer protected implementation details;
• attempting to modify the sealed runtime;
• attempting to access protected identity tails;
• attempting to extract derivation salts or protected parameters;
• attempting to interfere with the confidential computing environment;
• attempting to use the test environment for production transactions; or
• introducing real digital assets into the testnet environment.

Aveum may technically terminate, suspend, isolate, or disable a test environment if it detects activity that threatens the security, integrity, or operation of the evaluation infrastructure.

12. CONFIDENTIAL INFORMATION

The evaluation may expose the evaluator to information that Aveum regards as confidential or proprietary, including technical architecture, system workflows, enclave configuration, cryptographic methods, vault configuration, implementation details, and other non-public information.

This disclosure should not be interpreted as granting the evaluator ownership or intellectual-property rights in any such information.

Any confidentiality obligations applicable to the evaluator shall arise only under a separate confidentiality agreement, NDA, license, or other written instrument expressly imposing such obligations.

This Disclosure & Evaluation Notice itself is not intended to constitute a standalone confidentiality agreement.

13. NO PRODUCTION RIGHTS

Nothing in this disclosure provides the evaluator with a right to:

• deploy the Aveum protocol in production;
• process real genomic data;
• connect a national identity database;
• integrate Aveum into a government production environment;
• sublicense Aveum technology;
• access Aveum source code;
• modify Aveum's protected kernel or derivation systems;
• reproduce the production GIS;
• operate the production confidential-computing infrastructure; or
• commercially deploy the AVEUM Family Vault.

Any such rights require separate written authorization and, where applicable, a separate Aveum Institutional Full Master License Agreement.

14. NO AUTOMATIC COMMERCIAL CONVERSION

Completion of the evaluation does not create an obligation on either side to proceed with a commercial relationship.

The evaluation does not automatically convert into:

• a commercial license;
• a production license;
• a five-year license;
• a ten-year license;
• a financing;
• an investment;
• a partnership;
• a government deployment; or
• any other commercial transaction.

Any such relationship must be separately documented.

15. TEST ENVIRONMENT DISCLAIMER

The Family Vault evaluation is provided solely for technical evaluation and demonstration.

The evaluation environment may differ from the production environment in architecture, performance, data scope, availability, security configuration, supported functions, network configuration, token configuration, and other respects.

The test environment should not be relied upon as a representation of final production specifications.

16. CHANGES TO THE TEST ENVIRONMENT

Aveum may modify, update, replace, suspend, or discontinue components of the test environment as necessary for security, infrastructure, testing, maintenance, development, or operational reasons.

This may include changes to:

• the confidential computing deployment;
• the MPC integration;
• testnet configuration;
• evaluation-key architecture;
• test GIS configuration;
• synthetic-data generation;
• technical processing workflows; and
• other components of the evaluation infrastructure.

Such technical changes do not create or modify production rights.

17. SEPARATE CONTRACTUAL DOCUMENTS

Where Aveum requires legally binding terms for a particular evaluation, deployment, license, confidentiality obligation, commercial transaction, or production use, Aveum may provide a separate written instrument specifically identified as a contract, license, NDA, or other binding agreement.

The applicable binding instrument will identify its own:

• parties;
• effective date;
• scope;
• obligations;
• term;
• governing law;
• dispute-resolution mechanism; and
• other contractual provisions.

This Disclosure & Evaluation Notice should not be interpreted as replacing such a document.

18. ACKNOWLEDGMENT OF DISCLOSURE

By proceeding to activate the AVEUM Family Vault evaluation, the evaluator acknowledges that:

1. the evaluation is a controlled technical demonstration;
2. the test environment uses synthetic genomic data;
3. real genomic data must not be submitted;
4. the evaluation operates for approximately twenty-four (24) hours;
5. testnet digital assets should not be treated as having monetary value;
6. the evaluator should not place real digital assets into the test environment;
7. the test environment may be associated with technical device and network identifiers for security and test administration; and
8. production access requires separate authorization and documentation.

This acknowledgment is intended to confirm receipt and understanding of the disclosure. It is not intended to constitute acceptance of a license, arbitration agreement, commercial contract, or other separate contractual arrangement.

19. EVALUATION CONTACT